February 9, 2017

Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up

.   .   

This is a multicenter, randomized, controlled trial conducted at 31 French hospital. Patients with biopsy-proven PMN and nephrotic syndrome after 6 months of nonimmunosuppressive antiproteinuric treatment (NIAT) were randomly assigned to 6-month therapy with NIAT and 375 mg/m2 intravenous rituximab on days 1 and 8 (n=37) or NIAT alone (n=38). During the observational phase, remission rates […]

Leave a Comment! Posted in Clinical Nephrology, Clinical Trial Results, Glomerulonephritis
February 9, 2017

The Effect of Predialysis Fistula Attempt on Risk of All-Cause and Access-Related Death

.   .   

This is a retrospective cohort study of 2300 patients aged ≥18 years who initiated hemodialysis between 2004 and 2012 at five Canadian dialysis programs. The authors observed significantly lower mortality in individuals who underwent a predialysis fistula attempt than in those without a predialysis fistula attempt in patients aged <65 years and in the first […]

Leave a Comment! Posted in Chronic Kidney Disease, Clinical Nephrology, Clinical Trial Results, Hemodialysis, Vascular Access
February 9, 2017

Update on Nephrolithiasis: Core Curriculum 2016

.   .   

This core curriculum nicely review nephrolithiasis.  

Leave a Comment! Posted in AJKD Core Curriculum, Nephrolithiasis
February 9, 2017

DASH (Dietary Approaches to Stop Hypertension) Diet and Risk of Subsequent Kidney Disease

.   .   

This trial looked Atherosclerosis Risk in Communities (ARIC) Study participants with baseline estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m2 (N = 14,882).  3,720 participants developed kidney disease during a median follow-up of 23 years. Participants with a DASH diet score in the lowest tertile were 16% more likely to develop kidney disease than those with the highest score tertile […]

1 Comment Posted in Clinical Nephrology, Clinical Trial Results, General Nephrology, Hypertension
February 9, 2017

Comparative Effectiveness of 12 Treatment Strategies for Preventing Contrast-Induced Acute Kidney Injury: A Systematic Review and Bayesian Network Meta-analysis

.   .   

This systematic review included 150 trials with 31,631 participants and 4,182 contrast-induced AKI events assessing 12 different interventions. The conclusion was that high-dose statin plus NAC or high-dose statin alone were ranked the one/two for preventing contrast-induced AKI with no significant changes noted in metaregressions or subgroup and sensitivity analyses.  

Leave a Comment! Posted in Acute Kidney Injury, Contrast Nephropathy
November 19, 2016

Liraglutide and Renal Outcomes in Type 2 Diabetes: Results of the LEADER Trial

ASN 2016 High Impact Clinical Trial Johannes F. Mann, Kristine Brown Fandsen, Gilbert Daniels, Peter Kristensen, Michael Nauck, Steve Nissen, Stuart Pocock, Neil Poulter, Soren Rasmussen, William Steinberg, Mette Stockner, Bernard Zinman, Florian Baeres, Richard Bergenstal, Steve Marso, John Buse. Erlangen, Germany. Liraglutide, as compared to placebo, was studied in a RCT of 9340 high-risk […]

Leave a Comment! Posted in Clinical Trial Results, Conference Alert
November 19, 2016

Remote ischaemic preconditioning (RIPC) leads to sustained improvement in allograft function following live donor (LD) kidney transplantation: 5 year follow up in the REnal Protection Against Ischaemia Reperfusion in transplantation (REPAIR) study

ASN 2016 High Impact Clinical Trial Kristin Veighey, Jennifer Nicholas, Tim Clayton, Raymond Macallister Using 4 cycles of ischemia/reperfusion in the preoperative living donors, remote ischemic preconditioning (RIPC) was evaluated regarding its impact on post-tranplant outcomes.  The primary endpoint was iohexal GFR at 12 months and secondary endpoints were change in eGFR, graft loss or death. […]

Leave a Comment! Posted in Clinical Trial Results, Conference Alert
November 19, 2016

Efficacy and Safety of Sparsentan, a Dual Angiotensin II (Ang II) and Endothelin (ET) Type A Receptor Antagonist, in Patients with Focal Segmental Glomerulosclerosis (FSGS): A Phase 2 Trial (DUET)

High Impact Clinical Trials ASN 2016 Howard Trachtman, Peter J. Nelson, Radko Komers In the phase 2 DUET trial that included 96 patients with focal segmental glomerulosclerosis (FSGS), sparsentan, a dual angiotensin II and endothelin type A receptor antagonist, was evaluated to determine the impact on proteinuria. As compared to irbesartan, urinary protein excretion was […]

2 Comments Posted in Clinical Trial Results, Conference Alert
November 19, 2016

AURA-LV: Successful Treatment of Active Lupus Nephritis with Voclosporin

ASN 2016 High Impact Clinical Trial William Franklin Pendergraft, James A. Tumlin, Brad H. Rovin, Mary Anne Dooley, David R.W. Jayne, David Wofsy, Frederic A. Houssiau, David Isenberg, Tak Mao Chan, Neil Solomons, Robert B. Huizinga In patients with biopsy proven lupus nephritis, complete remission at 24 weeks was reached by 32.6% (p = 0.045) […]

18 Comments Posted in Clinical Trial Results, Conference Alert
November 19, 2016

The Sodium Lowering in Dialysate (SoLID) Trial: A Randomised Controlled Trial of Low versus Standard Dialysate Sodium Concentration (DNa) during Hemodialysis (HD) for Regression of Left Ventricular (LV) Mass

ASN 2016 High Impact Clinical Trial Mark R. Marshall, Alain C. Vandal, Joanna Leigh Dunlop, Janak Rashme de Zoysa, Imad A. Haloob, Christopher J. Hood, John Irvine, Philip J. Matheson, David Mcgregor, Kannaiyan Samuel Rabindranath, David Semple. Auckland, New Zealand. Dialysate sodium (Na) concentration of 135 mmol/L vs 140 mmol/L did not effectively reduce left ventricular […]

1 Comment Posted in Clinical Trial Results, Conference Alert
November 19, 2016

ASN 2016 Rabbit-ATG or Basiliximab Induction for Rapid Steroid Withdrawal after Renal Transplantation: An Open-Label, Multicentre, Randomized Controlled Trial

High Impact Clinical Trial Session at the 2016 ASN Christian Hugo, Michael Sean Wiesener, Mirian Opgenoorth, Oliver Thomusch. Dresden, Germany In low-tacrolimus treated, immunologically low-risk renal transplant recipients, rapid steroid withdrawal is safe with no impact on survival or biopsy-proven acute rejection.  Post-transplantation diabetes incidence is reduced from 39.2% to 23.9%(Basiliximab) or 22.7% (rATG) in […]

Leave a Comment! Posted in Clinical Trial Results, Conference Alert
November 11, 2016

The Risk of Major Hemorrhage with CKD

.   .   

This retrospective cohort study (2002-2010)  grouped 516,197 adults ≥40 years old by eGFR (≥90, 60 to <90, 45 to <60, 30 to <45, 15 to <30, or <15 ml/min per 1.73 m(2)) and urine albumin-to-creatinine ratio (ACR; >300, 30-300, or <30 mg/g) to examine incidence of hemorrhage. The 3-year cumulative incidence of hemorrhage increased 20-fold across declining eGFR […]

Leave a Comment! Posted in Chronic Kidney Disease, Clinical Nephrology, General Nephrology
November 11, 2016

Proton Pump Inhibitors and Risk of Incident CKD & Progression to ESRD

.   .   

The Department of Veterans Affairs national databases were used in this study to build a primary cohort of new users of PPI (n=173,321) and new users of histamine H2-receptor antagonists (H2blockers; n=20,270.  These patients were followed for over 5 years to ascertain renal outcomes. In adjusted Cox survival models, the PPI group, compared with the […]

Leave a Comment! Posted in Chronic Kidney Disease, Clinical Nephrology, General Nephrology